{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:26:54Z","timestamp":1787830014319,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The availability of the tyrosine-kinase inhibitor (TKI), imatinib, and later introduction of second generation TKIs, dasatinib and nilotinib, have not only improved clinical outcomes of patients with chronic myeloid leukemia (CML), but also provide multiple therapeutic options for CML patients. Despite the widespread use of these oral therapies, little is known about the impact of different treatment regimens on patient-reported outcomes (PROs) among CML patients. The objective of this study was to assess the impact of patient-reported treatment restrictions and negative medication experiences (NMEs) on satisfaction and other health outcomes among patients with CML treated with oral TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants recruited from survey panels and patient networks in the United States (US) and Europe completed an online questionnaire. Respondents included adults (\u226518 years) with chronic-phase CML currently on TKI treatment. Study variables included treatment difficulty (i.e., difficulty in following treatment regimens), CML dietary\/dosing requirements, NMEs, and validated PROs assessing treatment satisfaction, health-related quality of life (HRQoL), activity impairment, and non-adherence. Structural equation models assessed associations among variables, controlling for covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>303 patients with CML (US n=152; Europe n=151; mean age 51.5 years; 46.2% male) completed the questionnaire. Approximately 30% of patients reported treatment difficulties; treatment difficulty was higher among nilotinib (63.3%) than among dasatinib (2.6%) or imatinib (19.2%) treated patients (p&lt;0.0001). Non-adherence was generally low; however, patients on nilotinib vs. imatinib reported missing doses more often (p&lt;0.05). Treatment satisfaction was associated with significantly increased HRQoL (p&lt;0.05) and lower activity impairment (p&lt;0.01). NMEs were associated with decreased treatment satisfaction (p&lt;0.01) and HRQoL (p&lt;0.05), and greater activity impairment (p&lt;0.01). Higher overall treatment restrictions were associated with greater treatment difficulty (p&lt;0.001), which correlated with non-adherence (p&lt;0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment satisfaction and NMEs are important factors associated with HRQoL among patients with CML. Increased treatment restrictions and associated difficulty may affect adherence with TKIs. Choosing a CML treatment regimen that is simple and conveniently adaptable in patients\u2019 normal routine can be an important determinant of HRQoL and adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1477-7525-11-167","type":"journal-article","created":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T01:01:12Z","timestamp":1381194072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient\u2019s perspective"],"prefix":"10.1186","volume":"11","author":[{"given":"Ishan","family":"Hirji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaloo","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Goren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana R","family":"Chirovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson B","family":"Moadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Olavarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W","family":"Victor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,8]]},"reference":[{"key":"1217_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006, 56: 106\u2013130. 10.3322\/canjclin.56.2.106","journal-title":"CA Cancer J Clin"},{"key":"1217_CR2","volume-title":"SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations)","year":"2012","unstructured":"Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (Eds): In SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. based on November 2011 SEER data submission, posted to the SEER web site, 2012 http:\/\/seer.cancer.gov\/csr\/1975_2010\/sections.html"},{"key":"1217_CR3","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadi\u00e9 M, Simonetti A, Lutz JM, Berrino F, HAEMACARE Working Group: Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116: 3724\u201334. 10.1182\/blood-2010-05-282632","journal-title":"Blood"},{"key":"1217_CR4","first-page":"169","volume":"13","author":"S Faderl","year":"1999","unstructured":"Faderl S, Kantarjian HM, Talpaz M: Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park) 1999, 13: 169\u201380.","journal-title":"Oncology (Williston Park)"},{"key":"1217_CR5","unstructured":"The American Cancer Society. http:\/\/www.cancer.org\/cancer\/leukemia-chronicmyeloidcml\/detailedguide\/leukemia-chronic-myeloid-myelogenous-staging"},{"issue":"iii","key":"1217_CR6","first-page":"1","volume":"8","author":"K Dalziel","year":"2004","unstructured":"Dalziel K, Round A, Stein K, Garside R, Price A: Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004,8(iii):1\u2013120.","journal-title":"Health Technol Assess"},{"key":"1217_CR7","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD: The world health organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100: 2292\u2013302. 10.1182\/blood-2002-04-1199","journal-title":"Blood"},{"key":"1217_CR8","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.2146\/ajhp070482","volume":"15","author":"C Fausel","year":"2007","unstructured":"Fausel C: Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm 2007, 15: S9\u201315.","journal-title":"Am J Health Syst Pharm"},{"key":"1217_CR9","unstructured":"The American Cancer Society. http:\/\/www.cancer.org\/cancer\/leukemia-chronicmyeloidcml\/detailedguide\/leukemia-chronic-myeloid-myelogenous-treating-targeted-therapies"},{"key":"1217_CR10","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355: 2408\u201317. 10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"key":"1217_CR11","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqu\u00e9 C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362: 2260\u201370. 10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"key":"1217_CR12","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ: A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012, 120: 3898\u2013905. 10.1182\/blood-2012-02-410688","journal-title":"Blood"},{"key":"1217_CR13","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362: 2251\u20139. 10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"key":"1217_CR14","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet: Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27: 6041\u201351. 10.1200\/JCO.2009.25.0779","journal-title":"J Clin Oncol"},{"key":"1217_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4137\/CMO.S6416","volume":"5","author":"MP Shieh","year":"2011","unstructured":"Shieh MP, Mitsuhashi M, Lilly M: Moving on up: second-line agents as initial treatment for newly-diagnosed patients with chronic phase CML. Clin Med Insights Oncol 2011, 5: 185\u201399.","journal-title":"Clin Med Insights Oncol"},{"key":"1217_CR16","unstructured":"SPRYCEL (dasatinib) Tablet for Oral Use. Full Prescribing Information. Bristol-Myers Squibb; 2011. http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf"},{"key":"1217_CR17","unstructured":"TASIGNA (nilotinib) Capsules. Full Prescribing Information. Novartis; 2012. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tasigna.pdf"},{"key":"1217_CR18","unstructured":"GLEEVEC (imatinib mesylate) tablets for oral use. Full Prescribing Information. Novartis; 2012. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gleevec_tabs.pdf"},{"key":"1217_CR19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"15","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 15: 1809\u201320.","journal-title":"Blood"},{"key":"1217_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.critrevonc.2011.02.007","volume":"81","author":"F Efficace","year":"2012","unstructured":"Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, Baccarani M, Mandelli F, GIMEMA and EORTC Quality of Life Group: Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2012, 81: 123\u201335. 10.1016\/j.critrevonc.2011.02.007","journal-title":"Crit Rev Oncol Hematol"},{"key":"1217_CR21","volume-title":"Development of a cross-sectional survey to assess the experience of living with chronic myeloid leukemia (CML) from the patients\u2019 perspective. Poster session presented at: 15th Annual International Congress on Hematological Malignancies: Focus on Leukemias","author":"M Talpaz","year":"2011","unstructured":"Talpaz M, Victor TW, Chapnick J, Lorenzo R, Leighton S, Gupta S, Hirji I, Davis C: Development of a cross-sectional survey to assess the experience of living with chronic myeloid leukemia (CML) from the patients\u2019 perspective. Poster session presented at: 15th Annual International Congress on Hematological Malignancies: Focus on Leukemias, Lymphomas, and Myeloma. Whistler, Canada: International Congress on Malignancies; 2011."},{"key":"1217_CR22","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Barat\u00e8 C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F, GIMEMA: Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011, 118: 4554\u201360. 10.1182\/blood-2011-04-347575","journal-title":"Blood"},{"key":"1217_CR23","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1111\/j.1524-4733.2005.00073.x","volume":"8","author":"L Abetz","year":"2005","unstructured":"Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D, Copley-Merriman K, Hsu MA: Development of cancer therapy satisfaction questionnaire: item generation and content validity testing. Value in Health 2005, 8: S41-S53.","journal-title":"Value in Health"},{"key":"1217_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1524-4733.2007.00310.x","volume":"11","author":"PC Trask","year":"2008","unstructured":"Trask PC, Tellefsen C, Espindle D, Getter C, Hsu MA: Psychometric validation of the cancer therapy satisfaction questionnaire. Value in Health 2008, 11: 669\u201379. 10.1111\/j.1524-4733.2007.00310.x","journal-title":"Value in Health"},{"key":"1217_CR25","volume-title":"SF-12v2\u2122: How to Score Version 2 of the SF-12\u00ae Health Survey","author":"JE Ware","year":"2002","unstructured":"Ware JE, Kosinski M, Turner-Bowker DM, Gandek B: SF-12v2\u2122: How to Score Version 2 of the SF-12\u00ae Health Survey. Lincoln, RI: QualityMetric Incorporated; 2002."},{"key":"1217_CR26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","volume":"42","author":"JE Brazier","year":"2004","unstructured":"Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851\u2013859. 10.1097\/01.mlr.0000135827.18610.0d","journal-title":"Med Care"},{"key":"1217_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993, 4: 353\u2013365. 10.2165\/00019053-199304050-00006","journal-title":"Pharmacoeconomics"},{"key":"1217_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1037\/0033-2909.114.3.552","volume":"114","author":"SP Reise","year":"1993","unstructured":"Reise SP, Widaman KF, Pugh RH: Confirmatory factor analysis and item response theory: two approaches for exploring measurement invariance. Psychol Bull 1993, 114: 552\u201366.","journal-title":"Psychol Bull"},{"key":"1217_CR29","doi-asserted-by":"publisher","first-page":"II28","DOI":"10.1097\/00005650-200009002-00007","volume":"38","author":"RD Hays","year":"2000","unstructured":"Hays RD, Morales LS, Reise SP: Item response theory and health outcomes measurement in the 21st century. Med Care 2000, 38: II28\u201342.","journal-title":"Med Care"},{"key":"1217_CR30","volume-title":"MPlus (Version 6.1) [Computer Software]","author":"L Muth\u00e9n","year":"2010","unstructured":"Muth\u00e9n L, Muth\u00e9n B: MPlus (Version 6.1) [Computer Software]. Los Angeles: Muth\u00e9n & Muth\u00e9n; 2010."},{"key":"1217_CR31","first-page":"76","volume-title":"Structural equation modeling: Concepts, issues, and applications","author":"LT Hu","year":"1995","unstructured":"Hu LT, Bentler PM: Evaluating model fit. In Structural equation modeling: Concepts, issues, and applications. Edited by: Hoyle RH. Thousand Oaks: CA: Sage; 1995:76\u201399."},{"key":"1217_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"LT Hu","year":"1999","unstructured":"Hu LT, Bentler PM: Cutoff criteria for fit indices in covariance structure analysis: conventional criteria versus new alternatives. Structural Equation Modeling 1999, 6: 1\u201355. 10.1080\/10705519909540118","journal-title":"Structural Equation Modeling"},{"key":"1217_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1207\/s15327752jpa8701_03","volume":"87","author":"JB Ullman","year":"2006","unstructured":"Ullman JB: Structural equation modeling: reviewing the basics and moving forward. J Pers Assess 2006, 87: 35\u201350. 10.1207\/s15327752jpa8701_03","journal-title":"J Pers Assess"},{"key":"1217_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D: Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011, 35: 626\u201330. 10.1016\/j.leukres.2010.10.017","journal-title":"Leuk Res"},{"key":"1217_CR35","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/bjc.2012.348","volume":"107","author":"F Efficace","year":"2012","unstructured":"Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F: Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 2012, 107: 904\u20139. 10.1038\/bjc.2012.348","journal-title":"Br J Cancer"},{"key":"1217_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00277-011-1359-0","volume":"91","author":"S J\u00f6nsson","year":"2012","unstructured":"J\u00f6nsson S, Olsson B, S\u00f6derberg J, Wadenvik H: Good adherence to imatinib therapy among patients with chronic myeloid leukemia\u2013a single-center observational study. Ann Hematol 2012, 91: 679\u201385. 10.1007\/s00277-011-1359-0","journal-title":"Ann Hematol"},{"key":"1217_CR37","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28: 2381\u20138. 10.1200\/JCO.2009.26.3087","journal-title":"J Clin Oncol"},{"key":"1217_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ajh.22019","volume":"86","author":"P Ganesan","year":"2011","unstructured":"Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, Nandennavar M: Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011, 86: 471\u20134. 10.1002\/ajh.22019","journal-title":"Am J Hematol"},{"key":"1217_CR39","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D: Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011, 117: 3733\u20136. 10.1182\/blood-2010-10-309807","journal-title":"Blood"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7525-11-167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:44:44Z","timestamp":1630532684000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/1477-7525-11-167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,8]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1217"],"URL":"https:\/\/doi.org\/10.1186\/1477-7525-11-167","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,8]]},"assertion":[{"value":"27 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"167"}}